NCT00506701撤回不适用
Pilot Study to Investigate the Effect of Tadalafil on Secondary Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Change in 6 min. walking test
研究概览
简要总结
Tadalafil may lower the pulmonary artery pressure in patients with Chronic Obstructive Lung Disease and secondary pulmonary hypertension and thereby improve patients quality of life.
详细描述
Twenty outpatients with Chronic Obstructive Lung Disease (COPD) and secondary pulmonary hypertension are treated in a cross-over design with Tadalafil or placebo for 4 weeks. Primary effect parameter is 6 min. walking test.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 45 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis of Chronic obstructive lung disease
- •Exclusion Criteria
- •Patients with asthma
排除标准
- 未提供
研究组 & 干预措施
Tadalafil treatment 40 mg
Experimental
干预措施: Tadalafil (Drug)
结局指标
主要结局
Change in 6 min. walking test
时间窗: 6 months
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Sildenafil Therapy for Pulmonary Hypertension and Sickle Cell DiseaseSickle Cell DiseasePulmonary HypertensionNCT00492531National Heart, Lung, and Blood Institute (NHLBI)74
已完成
3 期
Sildenafil in HFpEF (Heart Failure With Preserved Ejection Fraction) and PHHeart Failure, DiastolicPulmonary HypertensionNCT01726049University Medical Center Groningen52
已完成
不适用
Phosphodiesterase Type 5 Inhibitors in Patients With Group 2 Pulmonary HypertensionGroup 2 Pulmonary HypertensionCpcPHNCT06350773Beni-Suef University66
已完成
2 期
Tadalafil for Pulmonary Hypertension Due to Chronic Lung DiseaseChronic Obstructive Pulmonary Disease (COPD)Pulmonary HypertensionNCT01862536VA Office of Research and Development44
尚未招募
不适用
Pilot Study assessing sildenafil effect on lung tumour blood flownon-small cell lung cancerlung cancer10038666NL-OMON31434Vrije Universiteit Medisch Centrum10